Abstract: Novel anti-viral compounds comprise phosphate-linked dimers of anti-viral nucleoside derivatives, or salts or esters of such nucleoside dimers. Pharmaceutical compositions containing the dimers and methods of treatment utilizing the same are disclosed.

Abstract: Aldosterone biosynthesis inhibitors having substantially no intrinsic antiandrogenic activity are disclosed as well as pharmaceutical compositions containing such compounds and methods of treatment utilizing these compositions.

Abstract: Method for controlling gastrointestinal dysmotility in humans by administration of opioid antagonists.

Abstract: A method of inducing anesthesia or conscious sedation while avoiding serious hypotensive episodes comprising the administration of a parenterally active benzodiazpine in conjunction with an opiate analgesic followed by the parenteral administation of from about 1 to about 3 mg of a long-acting pure narcotic antagonist. The antogonist may be administered during the time interval commencing immediately prior to the procedure and continuing until about 3-5 hours after administration of the opiate-benzodiazepine combination.

Abstract: A method of treating a human or animal patient suffering from an arthritic disease or associated inflammatory disease comprises daily administration to such patient of from about 1 to about 100 mg of the narcotic antagonists nalmefene or naltrexone. The nalmefene or naltrexone may be administered in equally divided doses from one to four times daily, preferably by the oral route. Parental administration may be utilized where suitable.

Abstract: A method of treating patients in chronic pain or suffering from chronic cough over a prolonged period to provide systemic analgesia or central antitussive effect while simultaneously avoiding the onset of intestinal hypomotility. The method includes the oral administration to the patient of dosage units comprising in combination opioid analgesics or antitussives and selected opioid antagonists which are substantially devoid of systemic antagonist activity when administered orally.

Abstract: Invention relates to 3-methylene substituted androst-4-ene-17-oxygenated compounds substituted with various substituents at the 10.beta.-position which are useful as inhibitors of estrogen biosynthesis.

Abstract: Novel compounds constituting esters of benzoic acids, selected from the group consisting of p-vinyl benzoic acid and p-ethynyl benzoic acid, with an aminoethanol selected from the group consisting of diethylaminoethanol and N-substituted aminoethanols. The esters have the formula ##STR1## where X is selected from the group consisting of ##STR2## or HC.tbd.C and each of R.sub.1 and R.sub.2 is selected from the group consisting of H, lower alkyls containing up to 6 carbon atoms and cycloalkyls. The novel compounds also include inorganic and organic acid salts of said esters. The novel compounds have a unique medicinal function as local subcutaneously-applied anesthetics which have a long-acting effect when administered without vasoconstrictors that heretofore have been used to prevent rapid dissipation of subcutaneously-applied local anesthetics.